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ABSTRACT
Purpose To investigate the agglomeration behaviour of the fine
(<5.0 μm) and coarse (>12.8 μm) particle fractions of salmeterol
xinafoate (SX) and fluticasone propionate (FP) by isolating aero-
dynamic size fractions and characterising their physicochemical
and re-dispersal properties.
Methods Aerodynamic fractionation was conducted using the
Next Generation Impactor (NGI). Re-crystallized control parti-
cles, unfractionated and fractionated materials were characterized
for particle size, morphology, crystallinity and surface energy. Re-
dispersal of the particles was assessed using dry dispersion laser
diffraction and NGI analysis.
Results Aerosolized SX and FP particles deposited in the NGI as
agglomerates of consistent particle/agglomerate morphology. SX
particles depositing on Stages 3 and 5 had higher total surface
energy than unfractionated SX, with Stage 5 particles showing the
greatest surface energy heterogeneity. FP fractions had compara-
ble surface energy distributions and bulk crystallinity but differ-
ences in surface chemistry. SX fractions demonstrated higher bulk
disorder than unfractionated and re-crystallized particles. Upon
aerosolization, the fractions differed in their intrinsic emission and
dispersion into a fine particle fraction (<5.0 μm).
Conclusions Micronized powders consisted of sub-populations
of particles displaying distinct physicochemical and powder dis-
persal properties compared to the unfractionated bulk material.
This may have implications for the efficiency of inhaled drug
delivery.
KEYWORDS dispersion . distribution . heterogeneity . inhaled
drug delivery . intra-batch variability . surface energy
INTRODUCTION
Dry Powder Inhaler (DPI) formulations generally consist of
micronized drug (<5.0 μm) in an agglomerated form which
may be blended with large crystals of lactose monohydrate
functioning as both a drug carrier and bulking agent. Fre-
quently, a fine particle excipient such as micronized lactose is
also incorporated into the formulation to help facilitate drug
particle de-agglomeration [1]. Pharmaceutical powders, how-
ever, are complex non-homogenous systems; this renders the
formulation of DPIs, such that high pulmonary delivery is
achieved, a challenge. Powder properties can vary widely;
for example, there is often a broad particle size distribution
(PSD) [2, 3] and this alone is a predominant factor in deter-
mining the mechanism and location of drug deposition in the
lungs [4]. The physicochemical properties of the particulate
system, such as particle size [5–7], shape [8], surface rough-
ness [9, 10], surface energy/interfacial chemistry [11–13] and
crystallinity [3, 14] are therefore crucial to the aerodynamic
behaviour of the DPI [2]. Such factors can influence the
aerosolization, in vitro and in vivo deposition profiles, and bio-
availability of the drug [1], and therefore have important
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consequences with regards to the efficacy of the inhaled
treatment.
In addition to the inherent variability in powder properties,
processing steps such as milling/micronization and blending
can often also introduce an additional source of particle
heterogeneity [15]. Micronization, although being a widely
adopted method for size reduction, can be inefficient and is
capable of inducing physical and chemical changes in particles
that can affect the performance of the inhaled formulation [1,
15–17]. The process of micronization also offers limited op-
portunity to control and/or manipulate particle properties
[18], such that inter-batch variability in surface energy [15,
19], powder flow [15], and cohesivity/agglomeration propen-
sity [20] can arise impairing the quality, efficacy and perfor-
mance of the final marketed product [15]. The blending
protocol employed during formulation can further alter pow-
der characteristics [21], and may result in changes to the
fluidisation and/or aerosolization behaviour of the powder
[21–23].
Another consequence of poorly controlled mechanical
comminution which is less well characterised is intra-batch
variability. Differing levels of processing stress experienced
across various sites within a powder bulk can lead to micro-
areas within the powder which possess different proper-
ties [24], and this may be manifest as altered flowability
and aerosol dispersion/de-agglomeration behaviour [24,
25]. Mechanically micronized powders also exhibit a
‘dynamic nature’ in which thermodynamically activated
amorphous sites on the surface of the particle can as a
function of time revert back to crystalline material [18].
Therefore any changes in powder properties, such as
surface energy and crystalline disorder, can further con-
tribute towards the potential for intra-batch differences
within powders.
Recently, the next generation impactor (NGI) has been
used to isolate powder fractions preparatively based on their
aerodynamic particle size [26]; this is achieved by dispersing
powder into the impactor and recovering deposited material
from the stages. By maintaining a constant flow rate through
the NGI, the aerodynamic particle size of the deposits can be
calculated. Operation of the impactor is not affected by the
physicochemical properties of the powder, thus by
characterising the fractions for their aerosol performance,
for example, any differences can be attributed to particle
physicochemical properties rather than aerodynamic size
[26].
The aim of this study was to investigate the agglomeration
behaviour of the fine (<5.0 μm) and coarse particle
(>12.8 μm) fractions of salmeterol xinafoate (SX) and
fluticasone propionate (FP) by isolating these aerodynamic
size fractions from micronized bulk powders. The fractions
were subjected to physicochemical characterisation to deter-
mine the particle size, morphology, crystallinity and surface
energy distribution, and an assessment of aerosol performance
was also made.
MATERIALS AND METHODS
Materials
Salmeterol xinafoate (SX) and fluticasone propionate (FP)
were obtained from Vamsi Labs, India (BN. SX-0081010)
and LGM Pharma, USA (BN. 5501-B-11030), respectively.
Cyclohexane was purchased from VWR International Ltd,
UK. Sorbitan monooleate 80 (Span 80) and polypropylene
glycol 400 (PEG400) were from Sigma Aldrich Ltd, UK.
Methanol (Fisher Scientific Ltd, UK) and ammonium acetate
(Chromanorn Hipersolv for HPLC, BDH Prolabo, VWR
International Ltd, UK) were high performance liquid chro-
matography (HPLC) grade. WhatmanTM nylon filters (pore
size 0.2 μm and 0.45 μm, diameter 47 mm) and hexane were
purchased from Fisher Scientific Ltd, UK. Polypropylene
glycol (average Mn approx. 1000) was from Sigma Aldrich
Ltd, UK, and size 3 gelatin capsules were from Capsugel,
France.
METHODS
Particle Preparation
Aerodynamic Fractionation
Aerodynamic fractionation was conducted as previously de-
scribed [26]. Powder (1–2 g) was aerosolized into the NGI
(MSP Corporation, USA, supplied by Copley Scientific, UK)
at a flow rate of 60 L.min−1 using a Malvern QSpec dry
powder feeder (DPF, Malvern Instruments Ltd., UK). The
NGI was assembled as described in the British Pharmacopoe-
ia 2012; solvent was not added to the pre-separator and the
plates were used uncoated. The vacuum pump (Twin
Impinger Model, TI2) and DPF were switched on for 2 min
during which powder was aerosolized into the impactor.
Following each 2 min interval, the NGI was dismantled, and
the powder deposits were carefully recovered using a plastic
scraper and transferred into clean, dry glass vials. This was
repeated until a yield of approximately 1 g was obtained in the
pre-separator and at least two of the fine particle stages for
each powder.
Amphiphilic Crystallization
Amphiphilic Crystallization was conducted as previously de-
scribed [27–30]. PEG400 solutions containing 4.5% w/w SX
or 0.65% w/w FP were prepared and subjected to high shear
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mixing (Model L4RT laboratory homogeniser, Silverson Ma-
chines, USA) at 2,100 rpm for SX and according to the
following protocol for FP: 2,000 rpm for 10 min, 3,000 rpm
for 10 min, and 1,000 rpm for 5 min. Following dissolution,
the solutions were degassed by ultrasonication for 5 min, and
filtered (0.2 μm hydrophobic PTFE syringe filter,
WhatmanTM). The addition of anti-solvent (water) was in
the ratio 1:11 (solution:water) for SX and 1:7 for FP, and
occurred at a rate of 20 g.min−1.g−1 of solution whilst being
stirred using an overhead stirrer (Model RZR 2051 2051,
Heidolph,UK) at 1,000 rpm for SX solutions, and ramped
from 700 to 1,430 rpm during the period of water addition for
FP solutions. The crystals were harvested by vacuum filtration
(0.2 μm nylon filter, WhatmanTM) and dried overnight at
50°C in a vacuum oven. The dried powder was washed with
200 mL cold water (4°C) with the aid of stirring at 1,470 rpm
for 5 min, harvested by filtration, and dried. The following
day the crystals were de-caked by sonicating (5–6 min) with
15 mL cyclohexane and vacuum drying (50°C) for 3 h.
Particle Characterisation
Particle Size Analysis
Laser diffraction particle sizing was carried out using a
Malvern Mastersizer X (Malvern Instruments Ltd, UK) fitted
with a 100 mm focal length lens (0.5–180 μm) and an MS7
magnetically stirred cell as described previously [31]. Drug-
saturated solvent dispersants were prepared consisting of Span
80 (0.5% w/v for SX, 0.1% w/v for FP) in cyclohex-
ane. Dispersants were sonicated for 30 min followed by
overnight stirring. Approximately 1 mg of drug was
added to 2 mL filtered dispersant (0.2 μm cellulose
acetate syringe filter) and sonicated for 5 and 2.5 min
for SX and FP respectively (Sonicleaner, DAWE, Ultra-
sonics Ltd, USA). A background reading was taken and
the suspension was added to the sample cell until the
obscuration was ~10–30%. Following equilibration
(60 s), ten individual measurements (measurement
sweeps 2500 for SX and 3500 for FP) were taken for
n=4–6 samples to obtain particle size measurements
calculated using Mie theory. Particle size metrics con-
sidered were the Dv10, Dv50, and Dv90, corresponding to
the particle size below which 10%, 50% and 90% of
the particles, by volume, are smaller, in the distribution.
Scanning Electron Microscopy (SEM)
Particle morphology was viewed using a Quanta 200 F field
emission scanning electron microscope (FEI UK Ltd, En-
gland) operated at 10 kV in low vacuum mode and using a
working distance of 10 mm. Powder samples were transferred
onto glass coverslips placed onto adhesive carbon tabs (Agar
Scientific, England) and mounted onto aluminium pin stubs
(Agar Scientific Ltd, England). Samples were sputter coated
with gold for 2 min to achieve a thickness of approximately
15–20 nm using a K550X sputter coater (Emitech, Quorum
Technologies Limited, England).
Powder X-ray Diffraction (PXRD)
Powder X-ray diffraction (PXRD) was conducted using a
Bruker D8 Advance X-ray diffractometer system (Bruker
AXS Ltd, USA). X-rays were generated by a copper (Cu)
source operated at a 40 kV tension and 40 mA current.
Powder samples were mounted onto a zero background sam-
ple holder and scanned from 2θ=4–30° for SX samples and
2θ=4–35° for FP samples, with a step size of 0.039° and count
time of 0.5 s per step.
Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry (DSC) thermographs
were generated using a Q Series differential scanning
calorimeter (Q20 – 5023 for SX samples, Q200 – 1934
for FP samples, both TA Instruments, UK). 1 mg of
sample was accurately weighed into an aluminium DSC
pan (TA Instruments, UK) and hermetically sealed; for
FP samples a pinhole was made in the lid prior to
sealing. SX samples were heated to 160°C at heating
rates of 0.1, 0.5, 1, 2, 5, 10, 20 and 40°C.min−1 and
FP samples were heated to 320°C at a heating rate of
2 0 °C .m i n− 1 , b o t h und e r a n i t r o g e n pu r g e
(50 mL.min−1). The DSC was calibrated at each
heating rate using an indium standard.
Thermo-kinetic Analysis of SX Re-crystallization
Thermo-kinetic analysis of SX re-crystallization involved
constructing α-heating rate curves, where α is the frac-
tion of SX-II re-crystallized from the melt [32]. α was
calculated using Equation 1, where ΔHf
βexp is the en-
thalpy of fusion of the SX-II polymorph at a given
heating rate, obtained from integration of the melting
endotherm, and ΔHf
β0.1 is the enthalpy of fusion at the
lowest heating rate employed (i.e. 0.1°C.min−1) where
complete conversion of SX-I to SX-II was assumed.
α ¼ ΔH
βexp
f
ΔH β0:1f
ð1Þ
The data were fitted to an Avrami-Erofe’ev-type equation
to determine the kinetic parameters k and n, representing the
integrated rate constant for the re-crystallization of SX-II and
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the Avrami exponent of the model respectively [32], where β
is the heating rate.
α ¼ 1−exp− k β−1ð Þ
n
ð2Þ
Inverse Gas Chromatography (IGC)
Surface energy analysis and specific surface area determina-
tion were conducted using an IGC Surface Energy Analyser
(SEA; Surface Measurement Systems Ltd, UK). Approxi-
mately 200 mg of sample was packed into individual pre-
silanised standard IGC glass column (300 mm in length, with
an internal diameter of 3 mm). Each column was pre-
conditioned in situ for 2 h at 30°C and 0%RH using helium
carrier gas. Non-polar probes (n-alkanes; n-nonane, n-octane,
n-heptane and n-hexane) and polar probes (ethyl acetate and
dichloromethane) were injected at a range of surface cover-
ages at 30°C using helium carrier gas at 10 sccm.Methane gas
was used for dead volume corrections.
The surface coverage was calculated using the Brunauer-
Emmett-Teller specific surface area (SSABET) of each sample
based on the n-octane adsorption isotherm data. This enabled
calculation of the monolayer capacity (nm, the number of
moles of solute adsorbed for monolayer coverage) using Equa-
tion 3, where am is the cross sectional area of a solute molecule
andNA is Avagadro’s number. The surface coverage (n/nm) at
each injection concentration could then be calculated from
the amount adsorbed (n) obtained from integration of the net
retention volume (VN) versus the equilibrium partial pressure
(P) of each injection [33].
SSABET ¼ am:N A:nm ð3Þ
The total surface energy (γT) was determined from sum-
mation of the dispersive and specific surface energy compo-
nents. The dispersive surface energy (γD) was determined by
measuring the VN of a series of n-alkane probes. The Dorris
and Gray method was employed in this work [34], whereby a
plot of RTln (VN) versus the carbon number of the n-alkanes
was generated for each surface coverage. The slope of the
linear regression represents the dispersive surface energy, and
subsequently enables the surface energy distribution to be
obtained.
Specific surface energy (γSP) can be determined by applying
the van Oss approach [35] and the Della Volpe scale [37]. γSP
was calculated as the geometric mean of an acid (Lewis
acceptor), gs
+, and a base (Lewis donor), gs , which were
determined from the injection of two monopolar probes of
opposite polarities; dichloromethane (γy124.58 mJ.m−2) and
ethyl acetate (γ−475.67 mJ.m−2). In order to do so, specific
free energy of desorption (ΔGSP) of the monopolar probes
were first obtained using the polarisation approach [36],
where a plot of RTln (VN) versus the molar deformation
polarisation of the probes (PD) was generated. The vertical
distance between each polar probe data point and the straight
line of the n-alkane data was equal to the ΔGSP of each polar
probe [36].
Surface energy distribution profiles were generated by
plotting the total, dispersive and specific surface energies at
the range of surface coverages employed. This allowed the
surface energy heterogeneity of the powders to be assessed.
Powder Dispersibility
Dry Dispersion Laser Diffraction
A recently developed laser diffraction data analysis technique
was undertaken to assess the de-agglomeration characteristics
of the powder [31]. Particle size measurements were made
using a Sympatec HELOS/RODOS (Sympatec GmbH,
Clausthal-Zellerfeld, Germany) employing the rotary feeder
and R3 lens (0.9-175 μm). Powder was hand-filled into the
rotating table and the latter operated at ’20%’ rotation prior
to the powder being drawn up into the dispersing line via a
protruding aspiration tube. Particle size measurements were
triggered to start when the optical concentration (Copt)
exceeded 1.1% and ceased when the Copt fell below 1% for
5 s (or 60 s real time). The timebase was 100 ms and a forced
stability of ‘4’ was applied. The primary pressure (PP) was
increased in the range 0.2 to 5.0 Bar. Particle size distributions
(Dv10, Dv50, Dv90 and VMD) were calculated using Fraunho-
fer theory and analyzed in WINDOX 4.0 software. Particle
size measurements for a complete titration curve were made
on a single day. Particle size-primary pressure profiles were
constructed in order to determine the critical primary pressure
(CPP, the dispersing pressure required for 100% de-
agglomeration) and DA50 (the dispersing pressure required
for 50% de-agglomeration) as described previously [31]. The
CPP provided an indication of the cohesive strength of the
powder and the DA50 is a measure of how readily powder
dispersion occurs.
Next Generation Impactor Analysis
Cascade impaction analysis was undertaken using the NGI
(n=3–4) connected to a vacuum pump. Impactor plates were
coated with 10 mL of coating solution (11% w/v polypropyl-
ene glycol in hexane) per plate to minimise particle bounce
and re-entrainment. The NGI was assembled with 15 mL
mobile phase in the pre-separator and attached to a vacuum
pump. Capsules were hand filled with 10±1 mg of drug
powder and loaded into a Monodose device (Miat SpA, Italy).
The flow rate through the NGI was adjusted to 60 L.min−1±
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5% and 1 capsule was actuated for 4 s per NGI run. The
device, capsules, throat, pre-separator and stages were rinsed
with mobile phase and sonicated to ensure complete dissolu-
tion of deposited powder prior to analysis by HPLC. The
stages were rinsed with 10 mL (stages 1–5) and 5 mL (stages
6–8) of mobile phase (with the aid of sonication) prior to
analysis by HPLC.
The following parameters were calculated.
& Recovered dose (RD) – the total recovered dose (TRD; i.e.
drug deposition in the device, capsules, throat, pre-
separator and impactor stages) expressed as a percentage
of the total actuated dose (i.e. powder mass weighed into
the capsule)
& Emission (ED) – the recovered dose excluding drug reten-
tion in the device and capsules, expressed as a percentage
of the TRD
& Fine particle fraction (FPF) – the percentage of the RD and
ED with a particle size<5.0 μm, determined from a log
normal-probability plot of the cumulative mass percent of
drug deposited on the impactor stages versus the stage cut
sizes
& Fine Particle dose (FPD) – the mass of deposited drug with a
particle size <5.0 μm, calculated by converting the FPF
into a mass using the TRD
& Mass median aerodynamic diameter (MMAD) and geometric stan-
dard deviation (GSD) – the median aerodynamic diameter
and geometric standard deviation of the drug obtained
from interpolation of the log normal-probability plot
High Performance Liquid Chromatography (HPLC) Analysis
Quantification of SX and FP recovery was effected using a
validated HPLC method [38]. A Waters Alliance HT 2795
separations module, aWaters 2996 photodiode array detector
and Waters column heater were used. The column was a
Phenomenex Luna C18 column (150 × 4.60 mm, 3 μm)
maintained at 40°C. The mobile phase consisted of
0.6% w/v ammonium acetate in ultrapure water (type 1+
graded with resistivity 18 MΩ-cm from a PureLab Ultra
system, Elga LabWater, UK) and methanol in the ratio
25:75 v/v and was filtered prior to use (0.45 μm nylon filter).
The mobile phase flow rate was 1 mL.min−1, the injection
volume was 20 μL and the run time was 6 min. The detection
wavelength was 228 nm. Samples were maintained at 10±
1°C in the autosampler chamber during analysis and peak
integration was conducted using Empower Pro software (Em-
power 2 software, Build 2154, Waters Corporation, USA).
Quantification was using pooled mixed standard calibration
curves (n=5) in the range 1–25 μg.mL−1 (R2; SX=0.999,
FP=0.998) and 40–400 μg.mL−1 (R2; SX=0.998, FP=
0.997). The limit of detection (LOD) and limit of
quantification (LOQ) were 0.2 μg.mL−1 and 0.7 μg.mL−1,
and 4.0 μg.mL−1 and 13.5 μg.mL−1 for the lower and upper
concentration ranges of SX, respectively. The LOD and
LOQ were 0.3 μg.mL−1 and 0.8 μg.mL−1, and 5.1 μg.mL−1
and 16.9 μg.mL−1 for the lower and upper concentration
ranges of FP, respectively.
RESULTS
Powder deposits were recovered from the NGI pre-separator
and stages 1–7 for SX and stages 1–6 for FP when the samples
were fractionated according to their aerodynamic particle
size. The largest proportion of the powder deposited in the
pre-separator, but within the impactor the maximum deposi-
tion occurred on stages 4 and 5 for SX, and stages 3 and 4 for
FP. Therefore, these fractions were selected for full
characterisation.
Particle Size and Morphology
The PSD of the samples was measured using liquid dispersion
laser diffraction. SX depositing in the pre-separator and stages
1–4 had comparable particle sizes to each other and to the
unfractionated material, despite the aerodynamic cut-off sizes
between the stages being different (Table I). Whereas previ-
ously the geometric particle size of powder fractions recovered
from stages 1–6 of the NGI following fractionation were
sequentially smaller [26], it was therefore postulated that in
the current study SX powder depositing in the pre-separator
and stages 1–4 remained agglomerated. Therefore agglomer-
ates with an equivalent aerodynamic size to the stage in
question deposited rather than discrete particles. SX deposit-
ing on stages 5, 6 and 7 showed a gradual shift towards a
smaller particle size suggesting the deposition of individual
particles may have occurred. A similar trend was observed for
FP; the liquid dispersed size of pre-separator and stage 1–4
powder deposits were comparable with each other and the
unfractionated material. There was a slight shift towards
smaller particle sizes for the powder depositing on stages 3
and 4 that was not seen with SX, and the FP powder depos-
iting on stages 5 and 6 had a smaller geometric size
representing fully dispersed powder particles (Table I). The
particle size of re-crystallized SX (Dv50=4.93±0.37 μm) and
FP (Dv50=3.62±1.43 μm) particles was larger than their
respective unfractionated powders; however, the Dv50 was
smaller than 5.0 μm, the required particle size for deposition
in the airways.
Particle and agglomerate morphology was unchanged be-
tween the fractionated and unfractionated powders (Fig. 1).
This indicates that the fractionation process did not obviously
alter particle shape, and that fractionated powders were ag-
glomerated. The re-crystallized particles exhibited a different
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morphology; SX particles were more plate-like and FP parti-
cles more needle-like following re-crystallization (Fig. 1).
Crystallinity
The PXRD diffractograms of the unfractionated, crystallized
and fractionated powders are shown in Fig. 2. The positions of
the peaks were the same between the different samples of each
powder demonstrating no change in polymorph between the
unfractionated, re-crystallized and aerodynamic size-
fractionated particles. DSC traces for SX samples were typical
for this drug, displaying an initial endotherm due to melting of
the SX-I polymorph, an exotherm due to the conversion of
SX-I to the SX-II polymorph, and a second endotherm due to
melting of SX-II. Increasing the heating rate revealed differ-
ences in the solid state disorder between the samples. A much
higher heating rate was required to suppress melting of the
SX-II polymorph for fractionated particles compared to
unfractionated and crystallized particles, suggesting greater
crystal damage. When modelled to a modified Avrami-
Erofe’ev equation, the kinetic parameters k and n,
representing the integrated rate constant for the re-
crystallization of SX-II and the Avrami exponent of the mod-
el, respectively, were determined (Table II). The Avrami
exponent was close to 2 for each sample, which is expected
for SX particles which have a platelet shape and therefore
predominantly grow in two directions [39]. The k values
revealed a different susceptibility to re-crystallization between
Table I The geometric equivalent volume particle size distribution (Dv10,
Dv50, Dv90) of unfractionated, crystallised, and aerodynamic size-fractionated
salmeterol xinafoate (SX) and fluticasone propionate (FP) sized using liquid
dispersion laser diffraction (mean±S.D., n=4 and 6, respectively) and the
aerodynamic cut sizes across the Next Generation Impactor when operated
at 60 L.min−1
Sample Aerodynamic Diameter (μm) Salmeterol xinafoate Fluticasone propionate
Minimum Size Mid-Point Size Dv10 (μm) Dv50 (μm) Dv90 (μm) Dv10 (μm) Dv50 (μm) Dv90 (μm)
Unfractionated n.a. n.a. 0.62±0.00 1.42±0.08 3.78±0.23 1.04±0.40 2.94±1.22 6.10±2.65
Crystallised n.a. n.a. 0.72±0.01 4.93±0.37 17.4±1.07 1.09±0.42 3.62±1.43 10.8±4.67
Pre-separator 12.8 n.a. 0.64±0.00 1.51±0.05 3.65±0.23 0.97±0.01 2.39±0.09 4.83±0.49
Stage 1 8.06 10.2 0.65±0.01 1.51±0.06 3.32±0.10 0.99±0.03 2.41±0.13 5.07±0.58
Stage 2 4.46 6.00 0.65±0.00 1.54±0.06 3.54±0.12 1.00±0.03 2.48±0.22 5.03±0.66
Stage 3 2.82 3.55 0.66±0.01 1.72±0.11 3.86±0.29 0.95±0.02 2.14±0.18 3.93±0.54
Stage 4 1.66 2.16 0.64±0.01 1.51±0.06 3.51±0.18 0.88±0.01 1.91±0.09 3.56±0.35
Stage 5 0.94 1.25 0.61±0.00 1.12±0.04 2.78±0.23 0.71±0.02 1.59±0.12 3.28±0.29
Stage 6 0.55 0.72 0.59±0.03 0.93±0.02 2.10±0.42 0.65±0.02 1.46±0.23 3.50±0.61
Stage 7 0.34 0.43 0.55±0.01 0.87±0.05 1.92±0.33 - - -
n.a. = not applicable
Fig. 1 Scanning electron micrographs of unfractionated, crystallized, and aerodynamically size-fractionated salmeterol xinafoate (SX) and fluticasone propionate
(FP) agglomerates at × 10500 magnification.
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the samples; stage 4 and 5 particles had comparable k values
whereas pre-separator particles had a much higher k value,
indicating a higher degree of crystalline disorder in these
particles. DSC traces for FP samples were typical for this drug
undergoing melting followed by degradation [40, 41]. There
was no change in the melting point between FP samples (data
not shown). Although a higher background and halo effect
was observable in PXRD diffractograms for stage 4 FP
(Fig. 2), this could not offer conclusive evidence of altered
crystallinity of FP samples due to the potential interference
of orientation effects with powders in this fine size range.
Surface Energy Distribution
The surface energy of the powders was characterised in terms
of the dispersive, polar and total surface energy (Fig. 3). The
results showed a gradual decrease in the surface energy value
as a function of surface coverage, and the extent of the decline
can be inferred as a marker of surface energetic inhomogene-
ity. For all the powders, the dispersive surface energy formed
themajor component of the total surface energy. Both SX and
FP re-crystallized particles had lower total surface energy than
the micronized (i.e. unfractionated) particles. For FP crystals,
the specific surface energy (relating to polar interactions) and
dispersive surface energy (relating to van der Waals interac-
tions) were both lower than the micronized ( i . e .
unfractionated) FP particles. For SX crystals, there was an
increase in the specific surface energy and a reduction in the
dispersive surface energy compared to the micronized (i.e.
unfractionated) SX particles.
In terms of the total surface energy, unfractionated and
Stage 4 SX powders had similar surface energy, Stage 3 SX
had slightly higher and more heterogeneous surface energy
than unfractionated SX, whereas Stage 5 particles had the
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Fig. 2 Powder x-ray diffractograms of unfractionated and crystallized salmeterol xinafoate (SX) and fluticasone propionate (FP) particles (n=1 displayed).
Table II The degree of re-
crystallisation (k) and Avrami com-
ponent (n) of pre-separator, stage 4
and stage 5 salmeterol xinafoate
(SX) samples (mean±SE, n=3)
Sample Degree of Re-crystallisation (k, °C−1.min) Avrami Component (n)
Pre-separator SX 8.12±0.26 2.08±0.17
Stage 4 SX 6.29±0.28 2.18±0.25
Stage 5 SX 6.66±0.27 1.96±0.18
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highest and most heterogeneous surface energies of all the
fractionated SX samples. Pre-separator SX had the lowest
surface energy of the fractionated material. For FP a different
trend was observed in that all the fractionated samples had
lower surface energy than the unfractionated FP powder
however the differences were small. Again, pre-separator FP
had the lowest surface energy of the fractionated samples.
Powder re-dispersal and aerosolization
The dispersibility of the powders was assessed using a laser
diffraction data analysis technique in which it is possible to
determine the ease of de-agglomeration (DA50) and cohesive
tendencies (CPP) of the powders (Table III). Following data
normalization and linearization as previously described [31],
the linearity was found to be good (R2 =0.892–0.998 for SX,
R2–0.906–0.968 for FP). For SX, in all instances (except for
Stage 5 particles), the DA50 was lower compared to
unfractionated SX suggesting an improvement in
dispersibility; pre-separator and Stage 4 particles showed the
largest improvement. For Stage 5 particles the DA50 was
comparable to that of the unfractionated SX indicating an
equally poor dispersibility. FP samples showed a different
behaviour. Pre-separator FP displayed a much larger DA50
value compared to the unfractionated FP indicating worsened
dispersibility. The remaining powders showed an improved
ease of dispersion with a rank order of Stage 4>crystallized>
Stage 3 FP in terms of a reducing DA50.
It was not always possible to deduce a measure of powder
cohesive strength according to the criteria previously de-
scribed [31]. This could arise from high heterogeneity in
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(a) Surface energy distributions of unfractionated, fractionated and crystallised salmeterol xinafoate
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(b) Surface energy distributions of unfractionated, fractionated and crystallised fluticasone propionate
Fig. 3 The dispersive, specific and total surface energy distributions of unfractionated, crystallized, and aerodynamic size-fractionated (a) salmeterol xinafoate (SX)
and (b) fluticasone propionate (FP) particles (NB the same legend is used for each graph).
Table III The primary pressure for 50% de-agglomeration (DA50) and
critical primary pressure (CPP) of unfractionated, crystallised and aerodynamic
size-fractionated salmeterol xinafoate (SX) and fluticasone propionate (FP)
assessed by dry dispersion laser diffraction
DA50 (Bar) CPP (Bar)
Salmeterol xinafoate
Micronised 1.45 3.50
Crystallised 1.21 n.a
Pre-separator 0.54 1.20
Stage 4 0.51 3.50
Stage 5* 1.40 3.00
Fluticasone propionate
Micronised 1.72 n.a.
Crystallised 1.05 3.50
Pre-separator 2.36 n.a
Stage 3 0.85 n.a.
Stage 4 1.50 n.a.
*Data modelled in the PP range 0.3 – 5.0 Bar; for all other samples PPs were
in the range 0.2 – 5.0 Bar; n.a. = not possible to assign a CPP.
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particle properties, incomplete de-agglomeration (even at the
highest dispersing pressure employed) or conversely particle
fracture/attrition occurring at high dispersing pressures. It
was therefore not possible to compare the CPP of the FP
samples. For SX, only pre-separator particles showed a re-
duction in cohesive strength compared to the unfractionated
powder (Table III).
Cascade impactor analysis also revealed differences in the
aerosolization of the samples (Table IV). For SX, the RDs
were in the range 72±2.6% to 87±1.3%. Despite a larger
particle size, re-crystallized SX exhibited a much higher emis-
sion (91±2.1%; one-way ANOVAwith post-hoc Tukey’s test,
p<0.05) than unfractionated particles (54±5.2%), potentially
due to reduced adhesion to device/capsule walls and lower
cohesivity facilitating flow and entrainment. However, an
increase in deposition in the throat and pre-separator for these
larger particles resulted in no overall change in the FPF
(p>0.05) compared to the unfractionated powder. Pre-
separator SX also exhibited higher emission (by approximate-
ly 10%) compared to unfractionated SX powder (p>0.05).
The FPF of pre-separator and unfractionated SX was un-
changed (p>0.05) such that although pre-separator particles
were entrained more readily, the de-agglomeration efficiency
was lower than for the unfractionated material. The emission
of unfractionated, Stage 4 and Stage 5 SX samples did not
differ significantly, and there was no change in FPF between
Stage 4 and the unfractionated powder (p>0.05). The FPF of
Stage 5 SX, however, was reduced compared to
unfractionated SX (p<0.05) suggesting poorer de-
agglomeration efficiency of the emitted mass.
FP samples exhibited different trends in aerosolization
compared to SX samples (Table IV). The RD of FP ranged
from 78±1.7% to 90±2.0%. The emission of re-crystallized
FP particles was unchanged compared to unfractionated FP
(p>0.05) however the FPF increased (p<0.05). The emission
of pre-separator, Stage 3 and Stage 4 FP was unchanged
compared to the unfractionated powder (p>0.05). The stage
fractions showed an increase in their FPF compared to
unfractionated FP (p<0.05), indicating an improvement in
de-agglomeration efficiency.
DISCUSSION
Particle production for delivery to the lungs commonly in-
volves crystallization followed by a comminution step such as
micronization in order to achieve an appropriate particle size
for deposition in the lungs. The highly energetic micronization
process can result in poor control over the physicochemical
properties of the particles with the potential for both intra-
and inter-batch variability [15]. A consequence of this could
be the generation of populations of particles which display
different physicochemical and aerosolization behaviour to the
bulk of the powder. For example, the introduction of amor-
phous regions onto crystalline drug surfaces can increase
surface energy and adhesive/cohesive forces [3, 42] such that
particles may be more difficult to fluidize and/or de-
agglomerate; there may even be a proportion of particles that
are so tightly agglomerated that they do not disperse during
delivery. A recently developed aerodynamic technique which
enables powders to be separated based on their aerodynamic
particle size [26] has therefore provided the possibility to
collect and study discrete powder fractions for their properties.
The fractionation methodology was extended in the current
Table IV The emission (% of the total recovered dose, RD), fine particle
fraction (FPF<5.0 μm, % RD and % emitted dose, ED), fine particle dose
(FPD<5.0 μm), mass median aerodynamic diameter (MMAD) and geomet-
ric standard deviation (GSD) of unfractionated, crystallised and aerodynamic
size-fractionated salmeterol xinafoate (SX) and fluticasone propionate (FP)
assessed by Next Generation Impactor analysis at 60 L.min−1 (mean±SD,
n=3–4)
Emission
(% RD)
Fine Particle Fraction
(% RD)
Fine Particle Fraction
(% ED)
Fine Particle
Dose (mg)
Mass Median Aerodynamic
Diameter (μm)
Geometric Standard
Deviation
Salmeterol xinafoate
Unfractionated 54.4±5.2 33.2±2.2 61.2±2.5 2.7±0.2 2.7±0.1 1.8±0.0
Crystallised 91.0±2.1 27.7±1.6 30.4±2.4 2.4±0.2 3.5±0.2 2.1±0.0
Pre-separator 64.1±6.9 38.4±4.6 59.8±2.4 3.0±0.4 2.6±0.1 1.8±0.0
Stage 4 47.3±3.9 33.8±5.1 71.3±6.0 2.7±0.5 2.5±0.1 1.8±0.0
Stage 5 44.8±2.6 20.6±1.9 45.9±2.9 1.4±0.0 2.7±0.1 2.0±0.0
Fluticasone propionate
Unfractionated 62.2±7.6 18.7±0.4 30.4±4.0 1.5±0.1 4.1±0.3 2.0±0.1
Crystallised 60.4±2.9 25.2±3.3 40.8±6.6 2.2±0.3 4.1±0.2 2.0±0.1
Pre-separator 68.2±4.1 22.3±0.8 32.9±2.8 1.8±0.0 4.1±0.1 2.1±0.2
Stage 3 59.6±3.4 31.6±1.7 53.1±0.8 2.5±0.1 3.7±0.1 1.9±0.0
Stage 4 58.7±3.6 30.5±0.6 52.1±2.9 2.5±0.1 3.5±0.1 1.9±0.0
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study to examine the physicochemical properties of aerody-
namically differentiated material, and therefore allow the
effect of intra-batch variability in particle properties present
within bulk powders to be determined.
During DPI delivery, powder agglomerates must disperse
within an airstream in order to attain a particle size which is
able to deposit in the lungs. For both SX and FP, the particle
size (expressed as the Dv50) of the pre-separator and stage
fractions (stage 1–3 for FP and stage 1–4 for SX) following
dispersion in liquid media were comparable to the
unfractionated powders (Table I) suggesting that the particles
remained agglomerated during fractionation and when de-
positing in the NGI. The stage cut sizes therefore represented
the aerodynamic size of the agglomerates rather than single
particles of equivalent size, shape or density. Categorical
evidence for the deposition of agglomerates within the cut-
off size ranges of impactor stages has not previously been
reported, although it has been postulated [26, 43]. The par-
ticle size of stage 4–6 deposits for FP, and stage 5–7 deposits
for SX, were smaller than the unfractionated particle size and
similar to the stage aerodynamic size range, suggesting that
these particles may have dispersed more fully prior to
deposition.
To provide a crystalline comparator, re-crystallized parti-
cles were produced by Amphiphilic Crystallization [27] such
that the particles would not possess any process-induced
changes to their physicochemical properties. Although the
re-crystallized particles were larger than the micronized (i.e.
unfractionated) material, the Dv50 was below 5.0 μm and
therefore likely to be within the aerodynamic size range suit-
able for pulmonary delivery. Achieving such a particle size is
one of the major challenges of controlled crystallization
methods, as small molecules tend to form relatively large
crystals (10–100 μm) and the crystal size distribution is depen-
dent on the crystallization conditions [1, 27, 28]. As the
primary aim was to obtain particles which had not been
subjected to secondary processing to function as control ma-
terial in terms of bulk and surface crystallinity, rather than to
obtain the smallest possible crystal size, the crystallization
method was not further optimized in this study.
Although there was no change in particle morphology, (by
visual assessment, Fig. 1) between the fractionated and
unfractionated powders, there were differences in other phys-
icochemical properties. PXRD analysis did not identify a
change in polymorphic form between any of the samples,
however, differences in crystallinity (subsequently referred to
as ‘bulk disorder’) were observed byDSC for SX samples. The
fractionated samples were found to have higher bulk disorder
than the unfractionated powder. The stage fractions had
comparable bulk disorder to each other, which in turn was
lower than the pre-separator fraction. Higher disorder may
arise from particle damage during powder processing such as
the use of micronization [44]. Levels of disorder generated are
dependent on the amount of energy imparted during size
reduction [16, 45] and milling time [46, 47]. It is understand-
able that a powder should show distribution in the degree of
disorder within a single batch of powder. The crystal damage
observed for fractionated SX samples may not have been
detected in the unfractionated material due to these more
severely damaged particles being present in a much smaller
proportion in the bulk material. Nevertheless, small quantities
of these particles may be important in terms of controlling the
dispersion of the bulk into the constituent particles upon
aerosolization. The most damaged particles were found to
have the lowest propensity for de-agglomeration during frac-
tionation, as particles in the pre-separator sample formed
larger agglomerates (>12.8 μm) compared to those of the
Stage 4 and 5 samples (0.55–1.66 μm).
Despite having the highest bulk disorder, pre-separator SX
particles had the lowest and least heterogeneous total surface
energy when compared to the unfractionated and stage frac-
tionated samples (Fig. 3). Stage 4 SX possessed near-identical
surface energy to unfractionated SX, with Stage 5 SX
displaying the highest andmost heterogeneous surface energy.
The smallest Stage 5 particles are likely to have been subjected
to the highest degree of particle attrition during comminution
and potentially demonstrate the greatest particle damage [16,
45–47], manifesting as high bulk (represented by the k value)
and surface (represented by the surface energy) disorder.
Higher dispersive surface energies have been reported with
increasing milling energy and grinding pressures, with an
inverse relationship with the geometric particle size (i.e. with
reducing size) resulting for drug particles following
micronization [48, 49]. These findings were attributed to
greater crystal disruption due to greater forces during
micronization, and the formation of new highly energetic
interaction sites and/or the exposure of more energetic crystal
faces [48, 49]. The balance of the dispersive and polar inter-
actions also differed between the fractionated samples, for
example, Stage 4 SX had higher and lower dispersive and
specific surface energies, respectively, than the unfractionated
powder, whereas for pre-separator SX the surface energies
were both lower than the unfractionated powder. This sug-
gests that size reduction of the particles may have occurred by
different particle size reduction mechanisms (e.g. brittle frac-
ture or attrition) and/or at different cleavage planes, resulting
in altered exposure of functional groups at the crystal surface
between the samples [49].
In contrast to SX, the differences in surface energy between
FP samples were overall less marked. Pre-separator particles
had the lowest total surface energy, whereas for the
unfractionated and stage fractions the surface energy could
be considered broadly comparable. Once more, differences in
the relative contributions of the dispersive and specific surface
energies were observed, indicating that the fractionated ma-
terials consisted of particles with differing electron donating
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and accepting functional groups at the exposed crystal surface
[49]. In addition, differences in the degree of surface energy
heterogeneity were observed for FP fractions.
Each powder fraction was found to display distinct aero-
solization behaviours when the fraction was considered as a
bulk powder and re-aerosolized. A powder composed of pre-
separator material would be likely to have a structure that
comprised of large agglomerates (>12.8 μm) exhibiting good
flow [50]. Low inter-agglomerate cohesive forces are likely
due to large agglomerate sizes, however, poor dispersal during
fractionation would suggest that intra-agglomerate cohesive
forces between the individual component particles was high.
Both SX and FP pre-separator samples were emitted in great-
er amounts and displayed a higher FPF than the respective
unfractionated powders (Table IV), although the differences
were not significant (p>0.05). Low inter-agglomerate cohesive
forces would assist the efficient entrainment of powder ag-
glomerates into the airstream during aerosolization. High
inter-particulate forces between individual particles may have
restricted the efficiency of the fractionation, but during re-
aerosolization of the smaller powder mass into the NGI then
the powder structure would be altered compared to the
unfractionated starting material. The efficiency of de-
agglomeration therefore depends on the balance between
high inter-particulate cohesive forces, and the higher aerody-
namic drag forces and kinetic energy experienced by large
agglomerates (compared to smaller agglomerates), which in
the latter case may increase de-agglomeration efficiency
through a greater number of collisions/impaction within the
device [49].
Changes in the intrinsic dispersibility of the pre-separator
fractions assessed by dry dispersion laser diffraction, however,
differed between the drugs and to the aerosolization behav-
iour seen in the NGI. Whereas the SX pre-separator sample
showed an improvement in the ease of de-agglomeration
(DA50), for FP the DA50 was worsened compared to the
respective unfractionated powders. The CPP also revealed a
difference in the cohesive strength of the fractionated SX
samples; there were no/small differences between the CPP
of the stage fractions, but the CPP of pre-separator SX was
lower than that of the unfractionated material, concurring
with the lowest total surface energy of this sample compared
to the stage fractions and unfractionated material. Whereas
cascade impactor analysis considers powder entrainability (i.e.
emission) and de-agglomeration efficiency (i.e. FPF) as sepa-
rate parameters, the ease of dispersibility (i.e. DA50) as deter-
mined using the laser diffraction technique incorporates the
flow, entrainment and de-agglomeration of the powder, inde-
pendent of the method of delivery (i.e. device and flow rate),
into a single, powerful parameter for assessing powder disper-
sion, along with enabling a measure of bulk powder cohesive
strength (CPP). A further advantage is that measurements take
into account every type of interactive force present, as well as
powder structure and history [31]. The structural character-
istics of a powder play an important role in dictating de-
agglomeration patterns [52, 53] and are influenced by the
physicochemical properties of the individual particles. The
work of cohesion (dependent on factors such as the surface
energy distribution of the particles), packing fraction (i.e. vol-
ume of particles/volume of agglomerate, and related to the
structure of agglomerates resulting from the magnitude and
distribution of interactive forces) and the size of the individual
particles, dictate powder structure, and can result in a lack of
structure homogeneity across the powder bed [52, 54]. It is
therefore necessary to consider both the fundamental
dispersibility of the powder and the powder delivery system,
including the device, formulation and flow rate, when
assessing powders for their de-agglomeration efficiency, and
developing delivery systems for optimized fine particle deliv-
ery to the lungs.
The aerosol performance of the stage fractions differed
between the drugs. Stage 4 SX, despite having an improved
DA50, showed no change in emission or FPF compared to
unfractionated SX. Stage 5 powder when re-aerosolized,
however, displayed a comparable, poor, DA50 and a reduced
FPF (p<0.05). When combined with the absence of change in
the emission, the high DA50 and reduced FPF indicated a
poorer de-agglomeration efficiency of Stage 5 SX. In this
instance, a combination of a small particle size (Table I), high
bulk disorder (Table II) and high surface disorder (Fig. 3)
resulted in a reduction in aerosol performance, where it is
likely that strong cohesive forces (CPP =3.0 Bar, Table III)
between the particles led to the formation of stable agglomer-
ates that were difficult to disperse [51]. Conversely, stage
fractionated FP (i.e. both Stage 3 and 4 particles) showed an
improvement in the DA50 and an increase in the FPF
(p<0.05), which alongside no change in emission indicated
an improvement in de-agglomeration efficiency compared to
unfractionated material. This improvement could not be at-
tributed to changes in crystallanity or (total) surface energy
between the unfractionated and stage fractionated FP parti-
cles, and highlights the complexity in the factors that influence
the de-agglomeration process. It was also not possible to
deduce a CPP for the unfractionated or fractionated FP
samples, despite a change in the DA50. The particle size-
dispersing pressure profiles were characteristic of micronized
powders and flattened as the dispersing pressure increased
[31], however, examination of this region of the curve indi-
cated that the particle size continued to reduce up to 5.0 Bar.
The magnitude of the reduction was small in comparison to
the early region of the curve (e.g. Stage 3 FP had a Dv50 of
12.29 μm, 2.75 μm and 1.80 μm at 0.2, 1.5 and 5.0 Bar,
respectively). It is likely that a combination of particle hetero-
geneity and particle fracture/attrition (as a result of high
dispersing pressures) resulted in the lack of a plateau region
according to the criteria previously described [31].
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The lower surface energy and larger size of the re-
crystallized control particles [30, 55] resulted in im-
proved dispersibility in terms of the DA50 for both
drugs, entrainability for SX and de-agglomeration effi-
ciency for FP compared to the unfractionated powders.
The FPFs of precipitated drug crystals have been shown
to be higher than jet-milled particles for both disodium
chromoglycate [14] and salbutamol sulphate [56], and
equivalent for SX [30]. FP crystals have demonstrated
improved [3], or similar FPFs [30] depending on the
crystallization conditions employed. In part, the im-
provements observed in this study are likely to arise
from the emission of the high energy micronization step,
however, other factors such as altered surface chemistry,
and changes to particle shape, particularly for FP, also
need to be considered and require further investigation.
The aerodynamic size fractions isolated in this study
were found to have their own distinct physicochemical
properties, which although in isolation could not fully
describe the different aerosolization behaviours of the
fractions, highlighted the consequences of intra-powder
variability on aerosol performance. It is generally ac-
cepted that a micronized powder will show a distribu-
tion in its particle size and surface energy, and we have
further demonstrated that it is possible to characterise
the sub-populations of a powder in these terms and
determine the effects on aerosolization. It is therefore
appropriate to consider powder properties as distribu-
tions when seeking to investigate and optimise de-
agglomeration behaviour rather than using ‘average’
values [25] which may not provide an accurate repre-
sentation of true powder character. In particular, the
ability to identify fractions of powders with optimal
dispersibiltiy may offer the opportunity to prepare
carrier-based blends of micronized powders with greater
homogeneity in powder blending and aerosolization
performances.
CONCLUSION
This study has demonstrated that SX and FP powders frac-
tionated into distinct aerodynamic size classes comprised of
sub-populations of the bulk micronized powder. These sub-
populations consisted of individual particles agglomerated to
varying extents and displaying distinct physicochemical prop-
erties of crystallinity and surface energy. It is important to
consider powders as collections of particle populations with
their own distinct properties; i.e. there is a need to consider
powder properties as distributions. By gaining better control
over the generation and properties of sub-populations of
particles, it may be possible to optimize the efficient delivery
of drug particles to the lungs.
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